Embedded Files
DelveInsight’s 2025 analysis of the Atopic Dermatitis Pipeline highlights over 100 major companies actively advancing more than 120 therapies for treating Atopic Dermatitis. This includes evaluations of clinical trials, therapeutic approaches, mechanisms of action, administration routes, and recent developments.
The Atopic Dermatitis Pipeline report offers thorough commercial and clinical evaluations of pipeline products, spanning from preclinical stages to marketed therapies. It details each drug's mechanism of action, clinical studies, regulatory approvals (such as NDAs if applicable), and development activities, including technological innovations, partnerships, mergers, acquisitions, funding, designations, and other relevant product information.
DelveInsight’s “Atopic Dermatitis Pipeline Insight, 2025” provides a complete overview of the current clinical development landscape and future growth opportunities in the Atopic Dermatitis market.
Key Highlights from the Atopic Dermatitis Pipeline Report
Pharmaceutical firms worldwide are actively innovating new treatments for Atopic Dermatitis, achieving notable progress in recent years.
Leading companies in the Atopic Dermatitis treatment sector include Pfizer, Kymera Therapeutics, BenevolentAI, AstraZeneca, Qurient, Sterna Biologicals, Vanda Pharmaceuticals, Arcutis Biotherapeutics, and others.
Promising therapies in various clinical trial phases, such as PF 07242813, KT-474, BEN2293, MEDI3506, Q301, SB011, Tradipitant, and Roflumilast, are anticipated to significantly influence the Atopic Dermatitis market soon.
In October 2025, the U.S. FDA granted approval for Zoryve® (roflumilast) cream 0.05% to treat mild to moderate Atopic Dermatitis in children aged 2 to 5. This decision relied on results from a Phase 1 pharmacokinetic study, the Phase 3 INTEGUMENT-PED trial (NCT04845620) with 652 pediatric participants (average body surface area affected: 22%), and the long-term INTEGUMENT-OLE extension study (NCT04804605).
In March 2025, Amgen and Kyowa Kirin revealed that their 24-week Phase III IGNITE trial for rocatinlimab—a therapy targeting T-cell balance in moderate to severe Atopic Dermatitis—met its primary goals. All secondary endpoints also showed significant improvements compared to placebo. The study, a double-blind, randomized, placebo-controlled trial, enrolled 769 adults, including those with prior biologic or JAK inhibitor treatments.
In March 2025, Hudson Therapeutics, the U.S. branch of Shaperon, announced the start of Phase 2b Part 2 for NuGel, an inflammasome inhibitor for mild to moderate Atopic Dermatitis. A U.S. kickoff meeting in March signified a milestone in NuGel's international clinical advancement.
Understanding Atopic Dermatitis
Atopic Dermatitis, often called eczema, is a long-term inflammatory skin disorder marked by red, itchy patches. It frequently recurs and is common in people with a history of allergies, such as asthma, hay fever, or allergic rhinitis.
Profiles of Emerging Atopic Dermatitis Drugs
PF 07242813: Developed by Pfizer.
KT-474: Developed by Kymera Therapeutics.
BEN2293: Developed by BenevolentAI.
MEDI3506: Developed by AstraZeneca.
Q301: Developed by Qurient.
SB011: Developed by Sterna Biologicals.
Tradipitant: Developed by Vanda Pharmaceuticals.
Roflumilast: Developed by Arcutis Biotherapeutics.
Atopic Dermatitis Therapeutic Assessment by Route of Administration
The report evaluates pipeline drugs based on administration methods, categorized as:
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Atopic Dermatitis Products by Molecule Type
Products are classified by molecular categories, including:
Recombinant fusion proteins
Small molecules
Monoclonal antibodies
Peptides
Polymers
Gene therapies
Download Sample PDF Report to know more about Atopic Dermatitis drugs and therapies
Atopic Dermatitis Pipeline Therapeutics Assessment
Assessment by Product Type: Includes monotherapy, combination therapy, or both.
By Stage and Product Type: Breakdown of therapies across development phases.
Assessment by Route of Administration: Analysis of delivery methods.
By Stage and Route of Administration: Phase-specific route evaluations.
Assessment by Molecule Type: Molecular structure analysis.
By Stage and Molecule Type: Phase-based molecular insights.
DelveInsight’s Atopic Dermatitis report covers approximately 120+ products in various clinical stages, such as:
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage products (Phase I)
Preclinical and discovery-stage candidates
Discontinued and inactive candidates
Key Companies in the Atopic Dermatitis Therapeutics Market
Major players advancing Atopic Dermatitis therapies include GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharmaceuticals Inc., AbbVie Inc., Allergan PLC, Bausch Health Companies Inc., Evelo Biosciences, Cara Therapeutics, Bristol-Myers Squibb Company, Sanofi S.A., LEO Pharma, and others.
Atopic Dermatitis Pipeline Analysis
The report offers insights into:
Detailed profiles of companies developing Atopic Dermatitis therapies, including the number of treatments per company.
Segmentation of therapeutic candidates into early, mid, and late development stages.
Companies engaged in targeted drug development, covering active and inactive projects.
Drugs in development, categorized by stage, administration route, target receptor, monotherapy or combination, mechanism of action, and molecular type.
In-depth review of partnerships (company-to-company or company-academia), licensing deals, and funding for market advancement.
The report draws from proprietary databases, company websites, clinical trial registries, conferences, SEC filings, investor presentations, press releases, and industry sources.
Atopic Dermatitis Pipeline Market Drivers
Increasing incidence of Atopic Dermatitis, rising healthcare costs, and promising new therapies are key factors driving market growth.
Atopic Dermatitis Pipeline Market Barriers
Availability of over-the-counter treatments, outdated guidelines, poor patient adherence, and other challenges hinder market expansion.
Scope of the Atopic Dermatitis Pipeline Insight
Coverage:Global
Key Companies: Pfizer, Kymera Therapeutics, BenevolentAI, AstraZeneca, Qurient, Sterna Biologicals, Vanda Pharmaceuticals, Arcutis Biotherapeutics, and others.
Key Therapies: PF 07242813, KT-474, BEN2293, MEDI3506, Q301, SB011, Tradipitant, Roflumilast, and others.
Therapeutic Assessment: Covers current marketed and emerging therapies.
Market Dynamics: Includes drivers and barriers in the Atopic Dermatitis market.
Additional details on Atopic Dermatitis products are available in the full report.
About DelveInsight
DelveInsight is a top-tier business consulting and market research firm specializing in life sciences. It assists pharmaceutical companies with end-to-end solutions to enhance performance and provides healthcare consulting services for market analysis, business acceleration, and practical problem-solving.
Contact Us
Kanishk
kkumar@delveinsight.com
Page updated
Google Sites
Report abuse